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ABSTRACT: In the area of drugs development, natural products represent a myriad of templates
for new lead medicines. This work identifies the uses of essential oils and terpenics/terpenoids
compounds by pharmaceutical industry through the granted patents databank from United States
Patent and Trademarks Office. One-thousand-two-hundred-ninety-eight documents have been
listed between 1980-2003 years. The most important pharmaceutical uses of essential oils and
terpenics/terpenoids compounds are as dermatological, antibiotics, analgesics, anti-inflammatory,
neurological, gastrointestinal, heart diseases and anticancer areas.
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INTRODUCTION
Plants synthesize the majority of known
organic substances that are used for the treatment of
illnesses that charged the humanity (Reinbothe et al.,
1990). Two examples are cancer and infectious
diseases treatment, where over 60% and 75% of the
drugs developed come from vegetable sources
(Newman et al., 2003). Amongst plants metabolites,
essential oils and their terpenics/terpenoids
compounds are characterized as the main chemical
compounds to be isolated and used by man (Craveiro
& Queiroz, 1993; Silva-Santos et al., 2004; Montanari
& Bolzani, 2001; Joulain, 1993).
The global market of pharmaceutical products
represents 33% of world-wide chemical compounds
RESUMO: Análise da utilização dos óleos essenciais e compostos terpênicos/terpenóides
pela indústria farmacêutica através das patentes concedidas pelo Escritório Norte-
americano de Marcas e Patentes (USPTO). Na área do desenvolvimento de fármacos, produtos
naturais são uma incrível fonte de inspiração para a obtenção de novas entidades químicas e/ou
medicamentos. Este trabalho identificou a utilização de óleos essenciais e compostos terpênicos/
terpenóides pela indústria farmacêutica mundial através das patentes concedidas pelo Escritório
Norte-americano de Marcas e Patentes (USPTO). Listou-se 1.298 documentos entre os anos de
1980-2003. As utilizações dos óleos essenciais e compostos terpênicos/terpenóides farmacêuticas
mais importantes estão nas áreas dermatológica, antibiótica, anagésica, antiinflamatória,
neurológica, gastrointestinal, doenças do coração e anticancerígenas.
Palavras-chave: óleos essenciais, terpenos, patentes, indústria farmacêutica, prospecção
tecnológica
9Rev. Bras. Pl. Med., Botucatu, v.10, n.1, p.8-15, 2008.
production (Newman et al., 2003, op.cit) and motivated
by the reduction of costs in research and development
(R&D) activities, the most important pharmaceutical
companies (Seidl, 2002) are investing in
bioprospective research to find new compounds to
synthesize new lead medicines. To protect these
investments, patents are the main mechanism used
by them, playing an important role in R&D programs
for the development of pharmaceutical products in
developed countries (Lozano, 2002; Araújo, 1984).
Besides the technological forecast has great
importance and extreme worth for companies and
governments nowadays, been characterized as a
continuous process that try to foresee situations and
environments at the same time that provides subsidies
to take decisions that will be more correct and
adjusted (Archibugi & Michie, 1995).
This work aims to show the relevance of
elaborating a database consisting of patents (USPTO,
2002/2004; Wilson, 1987) through a study between 1980-
2003, about the pharmaceutical uses of essential oils
and terpenics/terpenoids compounds, becoming possible
the identification of technological areas, owners, inventors,
varieties of essential oils, terpenics/terpenoids, etc.
METHODOLOGY
The databank was made by the keyword
(essential oil(s), terpenic(s) and terpenoid(s)) search
mechanism in the fields of ‘Claims’ and ‘Abstract’ of
USPTO (United States Patent and Trademarks Office)
granted patents documents. The technological
TABLE 1. Groups of International Patent Classification related with the use of essential oils and terpenics/terpenoids
compounds in the pharmaceutical sector
RESULT AND DISCUSSION
For the period of 1980-2003, had been
found 1,298 patents (Figure 1). Figure 2 details the
distribution of patents across the five groups of the
IPC showed in Table 1 and also detaches the main
sub-groups for each one.
The predominance for the application of
essential oils and terpenics/terpenoids compounds
have been as active ingredients for the therapeutical
action in the following groups: Dental preparations
(A61K 6/00), Medicinal preparations containing
organic active ingredients (A61K 31/00) and
Medicinal preparations containing material or
reaction products thereof with undetermined
constitution, like extracts of plants (A61K 35/
00), and, part ial ly, Medicinal preparations
characterized by special physical form (A61K
9/00). On the other hand, as non-active or
complementary ingredients, the uses of essential
oils and terpenics/terpenoids compounds are
character ized by the group A61K 47/00
(Medicinal preparations characterized by the
non-active ingredients used, e.g. carriers, inert
additives) and A61K 9/00 (Medicinal preparations
characterized by special physical form).
The application of essential oils and
terpenics / terpenoids compounds as
pharmaceutical active ingredients was indexed
by: A61K 6/02 preparations dentistry for artificial
teeth, for filling or for capping teeth; A61K 31/33
- Medicinal preparations containing Heterocyclic
compounds like organic active ingredients; A61K
9/10, about Medicinal preparations characterized
by special physical form like Dispersions or
Emulsions; A61K 9/14 - Medicinal preparations
characterized by special physical form like
Particulate Material; A61K 9/20 - Medicinal
knowledge for the use of essential oils and terpenics/
terpenoids compounds in the pharmaceutical sector
is indexed by the International Patent Classification
(IPC) (WIPO, 2002/2004) in Subclass A61K
(Preparations for medical, dental, or toilet purposes),
pertaining to Section A (Human Necessities) of IPC,
through the groups listed in the following Table 1.
Also it has been established a methodology
of analysis of documents, combining bibliographical
information from patents, like ‘cover page’, ‘abstract’
and ‘claims’ fields, capable to identify the following
items: a) Historical series; b) Essential oils; c)
Terpenics Compounds; d) Terpenoids Compounds; e)
Nature and nationality of the owners of patents rights;
f) Identification of the main owners and g) Application
that destines the invention.
Groups of IPC Discrimination  
A61K 6/00 Dental preparations  
A61K 9/00 Medicinal preparations characterized by special physical form  
A61K 31/00 Medicinal preparations containing organic active ingredients  
A61K 35/00 
Medicinal preparations containing material or reaction products thereof with 
undetermined constitution, like extracts of plant  
A61K 47/00 
Medicinal preparations characterized by the non-active ingredients used, e.g. 
carriers, inert additives 
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FIGURE 1. USPTO granted patents for the use of essential oils, terpenics/terpenoids compounds in the
pharmaceutical sector between 1980-2003.
Essential oils and terpenics/terpenoids
compounds
The matter identified in the ‘abstract’ and
‘claims’ disclose that amongst essential oils, 15 had
answered by 94.31% of 1,564 registered
bibliographical citations: a) condimentous essential
oils (sesame, clove, ginger, pepper, garlic), 599
citations; b) citrous essential oils (orange, lemon,
grapefruit and bergamot), with 376; c) mints essential
oils (peppermint and spearmint), 214 citations; d)
essential oils extracted from pine and eucalyptus,
respectively, with 129 and 73 citations; and e) floral
essential oils (rose and rosemary), 84 citations.
Table 2 shows the distribution for the uses
of these 15 main essential oils found in this search,
amongst the nine main sub-groups of the IPC listed
in previous Figure 2. The last column showed in
Table 2 indicates the percentage of participation of
each essential oil face the total of 1,564 joined
citations. The last line designates the joint
participation of 94.31% for these same essential oils.
About terpenics/terpenoids compounds
preparations characterized by special physical
form like Pills, lozenges or tablets; A61K 31/185 -
Medicinal preparations containing Acids,
Anhydrides, halides or salts thereof like organic
act ive ingredients;  A61K 31/70 Medicinal
preparations containing Carbohydrates, Sugars,
Der ivat ives thereof  l i ke  organ ic  ac t ive
ingredients; A61K 35/78 - Medicinal preparations
containing Materials from plants or reaction
products thereof with undetermined constitution;
and A61K 47/46 -  Medicinal  preparat ions
conta in ing ingred ients  o f  undetermined
const i tu t ion or  react ion products thereof
characterized for being non-active ingredients.
Figure 3 detailed the areas where essential oils
and terpenics/terpenoids compounds were used.
The register of use of essential oils in
patents was indexed by groups A61K 6/00, A61K
9/00, A61K 35/00 and A61K 47/00, and their
corresponding sub-groups. The application of
terpenes and terpenoids are centered in group
A61K 31/00 (and its sub-groups).
N0  of Patents                         N = 1,298
Year
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FIGURE 2. Groups and Subgroups from IPC applied in USPTO granted patents for the use of essential oils,
terpenics/terpenoids compounds in the pharmaceutical sector between 1980-2003. (A) A61K 47/46 - Medicinal
preparations containing Ingredients of undetermined constitution or reaction products thereof characterized by
theirs non-active ingredients; (B) A61K 6/02 - preparations for dentistry for artificial teeth, for filling or for capping
teeth; (C) A61K 9/20 - Medicinal preparations characterized by special physical form like Pills, lozenges or
tablets; (D) A61K 35/78 - Medicinal preparations containing Materials from plants or reaction products thereof with
undetermined constitution; (E) A61K 31/33 - Medicinal preparations containing Heterocyclic compounds like
organic active ingredients.
(Table 3), 15 had answered for 97.14% of 1,069
citations, like limonene (extracted from citrous
essential oils; 88 citations), camphor (extracted
from camphor essential oil; 192 citations), menthol
(extracted from mints essential oils; 305 citations)
and pinene (extracted from essential oils of the
species pine or eucalyptus; 41 citations).
Table 3 shows the distribution for the uses
of these 15 main terpenics/terpenoids compounds,
amongst the nine main sub-groups of the IPC listed
in previous Figure 2. The last column in Table 3
indicates the percentage of participation of each
compound face the total of 1,069 joined citations.
The last line designates the joint participation of
97.14% for these same substances.
The 1,298 patents belongs to following
groups of owners: a) 455 companies answering by
700 documents (or 53.93%); b) 46 researches
centers (governmental agencies, universities,
institutes and foundations) with 388 patents
(29.89%); and c) 168 Individually Owned Patent
(IOP) with 210 patents (16.18%). The most owners
were geoeconomically distributed by United States
(44.61%), Japan (12.40%) and Germany (5.24%).
Others nationalities (that had added 37.75%) were
Argentine, Australia, Belgium, Canada, China,
Colombia, Denmark, France, Great Britain, Greece,
India, Ireland, Israel, Italy, Mexico, Netherlands,
Portugal, South Korea, Spain, Sweden,
Switzerland, Taiwan and Uruguay.
About Individually Owned Patent (IOP),
North Americans answered by 70.48% of the 210
found patents, Japanese with 6.01% and French
by 5.23% (others nationalities had added 18.28%,
N = 1,298 patents
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FIGURE 3. Therapeutics areas described in the USPTO granted patents for the use of essential oils, terpenics/
terpenoids compounds in the pharmaceutical sector between 1980-2003. A: Dermatological compositions; B:
Antibiotic compositions; C: Analgesic compositions; D: Nutritional compositions; E: Antiinflamatories compositions;
F: Neurological compositions; G: Gastrointestinal compositions; H: Delivery System compositions; I: Adjuvant
compositions; J: Pharmaceutical tablets; K: Flavor compositions; L: Expectorant compositions; M: Heart diseases
treatment compositions; N: Anticancer compositions; O: Dental compositions; P: Osseous tissue compositions;
Q: Dietetical Compositions; R: Cholesterol Reducer compositions; S: Inductor to Cellular immunological response;
T: Antioxidant compositions; U: Ophtalmic compositions; V: Others (anaesthesic compositions; hair loss treatment;
procreation compositions; estabilizant compositions; enzyme inhibitors compositions; antidiabetic compositions;
antiallergic compositions; injectable formulations; erectile dysfunction treatment compositions; incontinence
treatment compositions; antitussive compositions; dysmenorrhea treatment compositions and endometriosis
treatment compositions).
see list above). The ratio between the total number
of IOPs listed and the total number of patents that
pertaining to IOPs was equal to 1:1.25. Table 4 list
the researches centers and its countries.
Also in companies, the ratio between the total
number of companies and the total number of patents
was low, equal to 1:1.54. Figure 4 shows the top 20
companies with an average ratio up than 10 patents/
firm. Amongst them, besides the 5 from top 10
pharmaceutical global firms (Pfizer (US),
GlaxoSmithKline (UK), Merck (US), Bristol-Myers
N0  of Patents
Squibb (US) e Aventis Pharma Group (FR/DE)) [14],
there are leader companies in the food, cosmetics
and personal care segments: L’Oreal (France;
cosmetic and cosmeceutic), Procter & Gamble (US;
personal care), Monsanto (US; nourishing
biotechnology) and Kimberly-Clark (US; personal care).
CONCLUSION
This study identified 1,298 granted patents
from United States Patent and Trademarks Office
Therapeutcs Areas
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TABLE 2. Most Important Essential Oils by Subgroups of A61K Subclass from IPC
A61K 31/33 - Medicinal preparations containing Heterocyclic compounds like organic active ingredients; A61K 35/78 - Medicinal
preparations containing Materials from plants or reaction products thereof with undetermined constitution; A61K 6/02 - preparations for
dentistry for artificial teeth, for filling or for capping teeth; A61K 9/10 - Medicinal preparations characterized by special physical form
like Dispersions or Emulsions; A61K 9/14 - Medicinal preparations characterized by special physical form like Particulate Material; A61K
9/20 - Medicinal preparations characterized by special physical form like Pills, lozenges or tablets; A61K 31/185 - Medicinal preparations
containing Acids, Anhydrides, halides or salts thereof like organic active ingredients; A61K 31/70 Medicinal preparations containing
Carbohydrates, Sugars, Derivatives thereof like organic active ingredients; A61K 47/46 - Medicinal preparations containing Ingredients
of undetermined constitution or reaction products thereof characterized por serem non-active ingredients.
TABLE 3. Most Important Terpenes and Terpenoids Compounds by Subgroups of Subclass A61K from IPC
A61K 31/33 - Medicinal preparations containing Heterocyclic compounds like organic active ingredients; A61K 35/78 - Medicinal
preparations containing Materials from plants or reaction products thereof with undetermined constitution; A61K 6/02 - preparations for
dentistry for artificial teeth, for filling or for capping teeth; A61K 9/10 - Medicinal preparations characterized by special physical form
like Dispersions or Emulsions; A61K 9/14 - Medicinal preparations characterized by special physical form like Particulate Material; A61K
9/20 - Medicinal preparations characterized by special physical form like Pills, lozenges or tablets; A61K 31/185 - Medicinal preparations
containing Acids, Anhydrides, halides or salts thereof like organic active ingredients; A61K 31/70 Medicinal preparations containing
Carbohydrates, Sugars, Derivatives thereof like organic active ingredients; A61K 47/46 - Medicinal preparations containing Ingredients
of undetermined constitution or reaction products thereof characterized por serem non-active ingredients.
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FIGURE 4. Top 20 USPTO granted patents owners companies related with the use of essential oils, terpenics/
terpenoids compounds in the pharmaceutical sector between 1980-2003. A - Univ.Texas System (US); B -
Conopco (US); C - Bayer (DE); D - Beth Israel Deaconeses Medical Centre (US); E - US Health Dept. (US);
F - KAO Corp. (JP); G - Takeda Co. (JP); H - Kimberly-Clark (US); I - Monsanto (US); J - American Home
Products (US); K - Council of Scientific and Ind. Research (IN); L - Scherinhg-Plough (US); M - Abbott (US);
N - Merck (DE); O - Brystol-Myers-Squibb (US); P - Pfizer (US); Q - GlaxoSmithKline (GB); R - Procter &
Gamble (US); S - L’Oreal (FR); T - Aventis Pharma Group. Country codes: DE – Germany; FR – France; GB
– Great Britain; IN - India; JP – Japan; US – United States of America. Aventis Pharma Group is a French-
German company formed in 1999, after merger of French Rhône-Poulenc and German Hoechst Marion Roussel
(HMR) – the pharmaceuticals division of the German Hoechst AG.
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N0  of Patents
Enterprises
related with the use of essential oils, terpenics/
terpenoids compounds in the pharmaceutical
sector  between 1980-2003.  The major
therapeutics uses were in the dermatological,
ant ib io t ic ,  ana lges ic ,  ant i - in f lammatory,
neurological, gastrointestinal, heart diseases
and anticancer areas. Among the essential oils,
three groups were the most cited: citrus, mints
and condimentous; and among terpenics/
terpenoids compounds: menthol and limonene.
Besides the expected list of pharmaceutical
companies, can be found three cosmetic and
personal care firms: L’oreal, Procter & Gamble and
Kimberly Clark. From the most important
therapeutic classes, six were rolled in this
research: Heart diseases, Central Nervous System,
Alimentary/Metabolism, Anti-infectious, Breathing,
Skeleton/Muscle.
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TABLE 4. List of Universities and Researches Centers
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